Compare Recursion Pharmaceuticals Inc (RXRX) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B), while Direxion Daily S&P 500 Bull 3X Shares trades at $295.18. The key difference: Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | SPXL | |
|---|---|---|
Market Cap | $1.81B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $6.79 | $296.39 |
52-Week Low | $2.84 | $170.20 |
Enterprise Value | $1.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.29, showing no change in the last session. The stock exhibits a bullish technical signal with moving averages supporting an uptrend, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported a Q2 2026 loss of $0.25 per share, missing estimates, with revenues declining year-over-year. Recent news highlights ongoing investor conferences and partnership advancements, such as Genentech optioning a neuroscience target, but profitability remains a challenge with a net income margin of -961.97% for 2026.
The outlook for RXRX is mixed, with analyst consensus leaning hold (60%) due to high cash burn and unproven commercial scalability. Investment opportunity lies in its AI-driven drug discovery platform and partnerships, but risks include sustained losses, competitive pressures, and reliance on milestone payments. The stock's trajectory hinges on pipeline success and cost management improvements.
SPXL, a leveraged ETF tracking the S&P 500, trades at $295.99, down 0.07% on the day, with technical indicators showing a bullish moving average trend but overbought RSI signals. The ETF reflects the S&P 500's record highs, driven by strong corporate earnings and AI optimism, though valuation concerns persist. Recent news highlights mixed sentiment, with JPMorgan raising its S&P 500 target to 8,000 while some warn of overvaluation risks.
The outlook for SPXL hinges on S&P 500 performance, offering amplified gains in a bullish market but heightened losses in downturns. Key opportunities include continued AI-driven earnings growth, while risks involve market volatility, inflation reports, and potential pullbacks from elevated levels. Investors should weigh leverage effects against broader index trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
